In April 2018, after a rigorous preregistered clinical trial that was published in the journal Nature Digital Medicine, the U.S. Food and Drug Administration (FDA) de novo authorized IDx-DR® the first autonomous AI system.  IDx-DR diagnoses (DR) and macular edema in adults who have diabetes and identifies those who need to be referred to eye care.   Two years later in November 2020, EyeArt® was 510k cleared by the FDA to market a similar device.  Based on claims data across all insured, only 15.3% of diabetic patients are receiving annual eye exams.  To tackle this gap in care, healthcare providers are implementing point-of-care tests utilizing autonomous AI technology to complete these diabetic retinal exams outside traditional eyecare settings.  This continuing education will not only reveal how AI technology is changing the way DR and macular edema are identified, but it will also help optometrists prepare for this rapidly evolving healthcare delivery model.

Course Code:



Dana Weitzman, O.D.



AOA Expiration Date:


Related News

Partners in care

A successful practice takes a village—doctors of optometry and paraoptometric staff—to make it work and even prosper. Toward that end, the AOA has created a trove of practice management tools and services that can power practices forward in a profession and health care landscape that increasingly demands doctors practice at their highest levels and creates greater opportunities to develop and empower paraoptometric staff. These days, change is out of necessity.

4 tips for handling payer clawbacks: What the experts say

A recent #AskAOA webinar, hosted by the AOA Third Party Center, offered helpful advice for how doctors can address and respond to clawbacks.

Webinar takes on sensitive topic of human trafficking

Most states require health care providers, including doctors of optometry, to report cases of abuse of children and elderly adults. AOA members are invited to attend an important webinar on the serious subject of human trafficking.